SmallCapReview.com - Small Cap Stocks To Watch - INNL, NEOT

WINSTON-SALEM, N.C. - April 5, 2017 - PRLog -- Gurnet Point L.P., a healthcare investment fund, and Innocoll Holdings (INNL) $1.82. Today announced that they have reached an agreement on the terms of a recommended offer. Under the recommended offer, Gurnet Point will acquire Innocoll for $1.75 per share in cash, and up to $4.90 in cash from a contingent value right (CVR), for a total potential per share value of up to $6.65 or up to approximately $209 million in aggregate. The initial cash consideration of $1.75 represents a premium of approximately 120 percent to the closing price per Innocoll Share on March 10, 2017, the last dealing day prior to the date on which the anomalous movement in Innocoll's shares commenced (and a premium of approximately 28 percent to the closing price per Innocoll Share on March 15, 2017, the day prior to Innocoll initiating the commencement of the offer period).

What They Do: Innocoll is a global, commercial stage specialty pharmaceutical and medical device company with late stage development programs targeting areas of significant unmet medical need. Innocoll's shares are listed for trading on the NASDAQ under the symbol "INNL."

Neothetics (NEOT) $1.55. Today announced the issuance of U.S. Patent Number 9,597,531 by the United States Patent and Trademark Office (USPTO).  This patent is directed to specific methods of using LIPO-202 and other agents for the reduction of fat accumulation. The '531 patent is expected to expire no earlier than the fourth quarter of 2031, extending the coverage time of the company's intellectual property portfolio. This is the eighth issued U.S. patent directed to Neothetics' lead product candidate LIPO-202, which is being evaluated for the reduction of submental fat.

What They Do: Neothetics is a San Diego based clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market.

To read more visit: http://www.smallcapreview.com

About SmallCapReview

Features available at SmallCapReview.com include in-depth profiles of select Small-Cap/Penny Stocks as well as the most comprehensive and up to date news available on the small-cap market.

No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. Nothing within our site should be construed as an offer or solicitation to buy or sell products or securities. The companies we profile may lack an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play.